# The Benefit of Hemodialysis Plus Hemoperfusion on Mortality

Study · id `cardio:ct-nct03227770` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03227770](<https://clinicaltrials.gov/study/NCT03227770>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03227770

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1362 participants.

## Technical summary

Registry record NCT03227770. Randomized; no masking; primary purpose treatment. Start 2017-12-01 (actual); primary completion 2021-12-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1362 participants (enrolled count; ClinicalTrials.gov record NCT03227770, source copy `cardio:ctgov-nct03227770-2022-08-29`, retrieved 2026-10-26)
- Started: 2017-12-01 (actual) (ClinicalTrials.gov record NCT03227770, source copy `cardio:ctgov-nct03227770-2022-08-29`, retrieved 2026-10-26)
- Primary completion: 2021-12-31 (actual) (ClinicalTrials.gov record NCT03227770, source copy `cardio:ctgov-nct03227770-2022-08-29`, retrieved 2026-10-26)
- Completion: 2021-12-31 (actual) (ClinicalTrials.gov record NCT03227770, source copy `cardio:ctgov-nct03227770-2022-08-29`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03227770, source copy `cardio:ctgov-nct03227770-2022-08-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03227770-2022-08-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Benefit of Hemodialysis Plus Hemoperfusion on Mortality
- Condition: End-stage Renal Disease
- Intervention (Device): hemoperfusion combined with hemodialysis
- Intervention (Device): hemodialysis
- Lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER
- Collaborator: Shanghai Zhongshan Hospital
- Collaborator class: OTHER
- Collaborator: RenJi Hospital
- Collaborator class: OTHER
- Collaborator: Ruijin Hospital
- Collaborator class: OTHER
- Collaborator: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Collaborator class: OTHER
- Collaborator: Shanghai 6th People's Hospital
- Collaborator class: OTHER
- Collaborator: Changhai Hospital
- Collaborator class: OTHER
- Collaborator: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Collaborator class: OTHER
- Collaborator: Shanghai University of Traditional Chinese Medicine
- Collaborator class: OTHER
- Collaborator: Shanghai Tongji Hospital, Tongji University School of Medicine
- Collaborator class: OTHER
- Collaborator: Yangpu District Central Hospital Affiliated to Tongji University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (`cardio:org-xinhua-hospital-shanghai-jiao-tong-university-school-of-9039af`)
- Registry lists this organization as a collaborator: Shanghai Zhongshan Hospital (`cardio:org-shanghai-zhongshan-hospital`)
- Registry lists this organization as a collaborator: RenJi Hospital (`cardio:org-renji-hospital`)
- Registry lists this organization as a collaborator: Ruijin Hospital (`cardio:org-ruijin-hospital`)
- Registry lists this organization as a collaborator: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-general-hospital-shanghai-jiao-tong-university-237209`)
- Registry lists this organization as a collaborator: Shanghai 6th People's Hospital (`cardio:org-shanghai-6th-people-s-hospital`)
- Registry lists this organization as a collaborator: Changhai Hospital (`cardio:org-changhai-hospital`)
- Registry lists this organization as a collaborator: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (`cardio:org-shanghai-ninth-people-s-hospital-affiliated-to-shanghai-d943b7`)
- Registry lists this organization as a collaborator: Shanghai University of Traditional Chinese Medicine (`cardio:org-shanghai-university-of-traditional-chinese-medicine`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Hemoadsorption combined with hemodialysis versus hemodialysis alone on mortality in end-stage kidney disease: a randomized, open-label, multicenter trial (`cardio:pubmed-41904134`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 134d2ade6de8b47d18cebb0449a541fd628e0f7f7f2b6c73141f7956311957c0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
